Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitus

This publication has 19 references indexed in Scilit:

• Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
  Diabetes, Obesity and Metabolism, 2021
• Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect
  Diabetes Therapy, 2020
• Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
  Annual Review of Physiology, 2020
• Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes
  Kidney International, 2020
• SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
  Nature Reviews Cardiology, 2020
• Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial
  Diabetes Care, 2020
• How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
  Diabetes Care, 2017
• Aortic pulse wave velocity predicts incident cardiovascular events in patients with type 2 diabetes treated in primary care
  Journal of Diabetes and its Complications, 2016
• Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
  The Lancet, 2016
• Prognostic Impact of Aortic Stiffness in High-Risk Type 2 Diabetic Patients
  Diabetes Care, 2013